M.D. Anderson Cancer Center: Urinary Bladder Neoplasms trials

The registry lists 30 Urinary Bladder Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 1 6Phase 2 15Phase 3 1Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Measuring Surgical Recovery After Radical CystectomyRecruitingNCT03193970
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedNCT04902040Phase 1/2Results posted
• Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE StudyTerminatedNCT04066894Phase 2Results posted
• Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyCompletedNCT03319745Phase 2Results posted
• Investigation of Sugammadex in Outpatient Urological ProceduresCompletedNCT03138967Phase 4Results posted
• Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the BladderCompletedNCT00963859Phase 2Results posted
• Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerCompletedNCT00749892Phase 2Results posted
• Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial CancerCompletedNCT00506155Phase 2Results posted
• Iressa and Taxotere Study in Patients With Metastatic Urothelial CancerTerminatedNCT00479089Phase 2Results posted
• Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney FunctionCompletedNCT00478361Phase 2Results posted
• A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle ContrastTerminatedNCT00147238Not applicableResults posted
• A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive, not recruitingNCT05137262Phase 2
• A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630Active, not recruitingNCT05055050Phase 1
• ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyTerminatedNCT03106610Phase 1
• Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved ImagingCompletedNCT02203136
• The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)Status unknownNCT01447199
• 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder CancerCompletedNCT01162785Phase 1
• Markers of Response to Intravesical Bladder Cancer TherapyCompletedNCT01007058
• Genetic Susceptibility to Bladder CancerActive, not recruitingNCT00848289
• Topical Cyclosporine vs. Placebo for Epiphora Associated With DocetaxelWithdrawnNCT00824811Phase 2
• Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the UrotheliumActive, not recruitingNCT00756639Phase 2
• Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial TumorsActive, not recruitingNCT00567684Not applicable
• Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsCompletedNCT00479128Phase 1
• Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During PregnancyCompletedNCT00310115
• Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the UrotheliumCompletedNCT00082719Phase 1
• Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal RemnantActive, not recruitingNCT00082706Phase 2
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the UrotheliumCompletedNCT00080795Phase 2
• Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder CancerCompletedNCT00004154Phase 3